Emicizumab

Generic Name

Emicizumab

Other Names

• Hemlibra

Drug Class

• Antihemophilic agent

Chemical Formula

C6636H10204N1768O2034S44

Molecular Weight

145584.9 g/mol

Mechanism of Action

• Acts as a bispecific monoclonal antibody that bridges activated FIX and FX, enhancing the activation of Factor X by Factor IXa

Indications

• Hemophilia A with or without Factor VIII inhibitors

Common Dosage Forms

• Solution for injection

Typical Dosage

• Initial loading dose, followed by maintenance doses

Pediatric Dosage

• Doses based on weight and severity

Geriatric Dosage

• Doses may need adjustment based on renal function

Side Effects

• Injection site reactions
• Thrombotic microangiopathy
• Thromboembolism
• Thrombosis at the catheter insertion site

Contraindications

• Known hypersensitivity to emicizumab

Pregnancy Category

• Category C - Animal reproduction studies have shown an adverse effect on the fetus

Lactation Safety

• Not recommended during breastfeeding due to limited data on excretion into human milk

Drug Interactions

• No significant drug interactions reported

Overdose Symptoms

• No specific symptoms

Antidote for Overdose

• No specific antidote, manage overdose symptomatically

Storage Conditions

• Refrigerate at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light

Pharmacokinetics

• Absorption: Absorbed slowly after subcutaneous injection
• Distribution: Binds specifically to activated coagulation factors
• Metabolism: Unknown
• Excretion: Elimination half-life is approximately 4 weeks

Precautions

• Monitor for signs of thrombosis and coagulation activation

Warnings

• Thrombotic microangiopathy and thrombotic events have been reported

Others

• Regular monitoring of coagulation parameters is essential during treatment